A Phase I Study of IBI325 in Patients With Advanced Solid Tumor
The primary objective of this phase I study is to evaluate the safety and potential efficacy and to determine the recommended phase 2 dose (RP2D) of IBI325 in patients with advanced solid tumors
Solid Tumor
DRUG: IBI325 + sintilimab|DRUG: IBI325
Number of patients with DLT, Number of patients who experienced a dose-limiting toxicity within the first 28 days after the first dose, 28 days post first dose|Number of patients with treatment related AEs, Number of patients who experienced a treatment related AEs from the first dose until 90days after the last dose, Up to 90 days post last dose
Number of patients with response, Number of patients with response per RECIST 1.1, Every 6 weeks until progressive disease or up to 24 months after treatment|The area under the curve (AUC), Up to 90 days post last dose|Maximum concentration (Cmax), Up to 90 days post last dose|Time at which maximum concentration (Tmax), Up to 90 days post last dose|The half-life (t1/2), Up to 90 days post last dose|Positive rate of ADA and Nab, Up to 90 days post last dose
The primary objective of this phase I study is to evaluate the safety and potential efficacy and to determine the recommended phase 2 dose (RP2D) of IBI325 in patients with advanced solid tumors